TWI862548B - 外用的磷脂肌醇3-激酶抑制劑 - Google Patents

外用的磷脂肌醇3-激酶抑制劑 Download PDF

Info

Publication number
TWI862548B
TWI862548B TW109103710A TW109103710A TWI862548B TW I862548 B TWI862548 B TW I862548B TW 109103710 A TW109103710 A TW 109103710A TW 109103710 A TW109103710 A TW 109103710A TW I862548 B TWI862548 B TW I862548B
Authority
TW
Taiwan
Prior art keywords
acid
compound
formula
formulation
weight
Prior art date
Application number
TW109103710A
Other languages
English (en)
Chinese (zh)
Other versions
TW202045513A (zh
Inventor
馬奇德 艾邁德 F 艾柏戴爾
艾吉斯 凱多紐斯
湯瑪士 羅西
福成 陳
Original Assignee
美商凡賽拉公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商凡賽拉公司 filed Critical 美商凡賽拉公司
Publication of TW202045513A publication Critical patent/TW202045513A/zh
Application granted granted Critical
Publication of TWI862548B publication Critical patent/TWI862548B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW109103710A 2019-02-06 2020-02-06 外用的磷脂肌醇3-激酶抑制劑 TWI862548B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962802093P 2019-02-06 2019-02-06
US62/802,093 2019-02-06
US202062958049P 2020-01-07 2020-01-07
US62/958,049 2020-01-07

Publications (2)

Publication Number Publication Date
TW202045513A TW202045513A (zh) 2020-12-16
TWI862548B true TWI862548B (zh) 2024-11-21

Family

ID=71835949

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109103710A TWI862548B (zh) 2019-02-06 2020-02-06 外用的磷脂肌醇3-激酶抑制劑

Country Status (14)

Country Link
US (2) US11661429B2 (cg-RX-API-DMAC7.html)
EP (1) EP3920911A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022519317A (cg-RX-API-DMAC7.html)
KR (1) KR20210124310A (cg-RX-API-DMAC7.html)
CN (1) CN114072144A (cg-RX-API-DMAC7.html)
AU (1) AU2020219065A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021015353A2 (cg-RX-API-DMAC7.html)
IL (1) IL285020B2 (cg-RX-API-DMAC7.html)
MA (1) MA54907A (cg-RX-API-DMAC7.html)
MX (1) MX2021009142A (cg-RX-API-DMAC7.html)
SA (2) SA521422728B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202108274SA (cg-RX-API-DMAC7.html)
TW (1) TWI862548B (cg-RX-API-DMAC7.html)
WO (1) WO2020163525A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202108274SA (en) 2019-02-06 2021-08-30 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
EP4192431A1 (en) * 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors
EP4401732A4 (en) * 2021-09-15 2025-09-24 Dermbiont Inc COMPOSITIONS AND FORMULATIONS FOR TOPICAL USE OF AN AKT INHIBITOR FOR THE PREVENTION, TREATMENT, AND AMELIORATION OF SKIN DISEASES, CONDITIONS, AND DISORDERS
CN115991716B (zh) * 2021-10-19 2025-10-17 中国药科大学 嘧啶并环类化合物及其衍生物、制备方法、药物组合物和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009978A1 (en) * 2000-04-27 2004-01-15 Masahiko Hayakawa Fused heteroaryl derivatives
WO2006046040A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
WO2016187157A1 (en) * 2015-05-15 2016-11-24 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5261001A (en) * 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
JP3602519B2 (ja) 2002-07-12 2004-12-15 コナミ株式会社 ビデオゲーム装置、画像処理方法及びプログラム
WO2007021933A2 (en) 2005-08-12 2007-02-22 The General Hospital Corporation Methods and compositions for use in treating vascular diseases and conditions
US8129371B2 (en) * 2007-10-16 2012-03-06 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mTOR kinase and PI3 kinase inhibitors
AU2008335156A1 (en) * 2007-12-10 2009-06-18 Metaproteomics, Llc Substituted 1,3-cyclopentadione multi-target protein kinase modulators of cancer, angiogenesis and the inflammatory pathways associated therewith
AU2008363813A1 (en) * 2008-11-07 2010-05-14 Children's Hospital Medical Center Fusogenic properties of saposin C and related proteins and peptides for application to transmembrane drug delivery systems
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
PT2385832E (pt) 2009-01-08 2015-11-02 Curis Inc Inibidores de fosfoinoritide 3-quinase com uma fração de ligação ao zinco
EP2510121A1 (en) 2009-12-11 2012-10-17 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
CN102268014B (zh) 2010-06-03 2015-06-03 上海艾力斯医药科技有限公司 一类稠合杂芳基衍生物、制备方法及其应用
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
BR112013008615B1 (pt) 2010-10-13 2021-05-11 Medivir Ab composição farmacêutica
CN104010494B (zh) 2011-07-28 2017-07-04 霍夫曼-拉罗奇有限公司 Pik3ca h1047r敲入非人动物乳腺癌模型
US8871781B2 (en) 2011-11-30 2014-10-28 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject for a lymphatic malformation
CN104379163A (zh) 2012-06-08 2015-02-25 霍夫曼-拉罗奇有限公司 用于治疗癌症的磷酸肌醇3激酶抑制剂化合物和化疗剂的突变选择性及组合
WO2014046617A1 (en) 2012-09-19 2014-03-27 Agency For Science, Technology And Research Compositions and methods for treating cancer
JP7051693B2 (ja) 2016-02-19 2022-04-11 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル PIK3CA関連過成長症候群(PROS CLOVaS症候群)の処置に使用するためのBYL719(アルペリシブ)
EP3251657A1 (en) 2016-05-30 2017-12-06 Sun Pharmaceutical Industries Limited Topical aqueous spray compositions of halobetasol
ES2893527T3 (es) 2016-12-28 2022-02-09 Hisamitsu Pharmaceutical Co Parche
SG11202108274SA (en) 2019-02-06 2021-08-30 Venthera Inc Topical phosphoinositide 3-kinase inhibitors
EP4192431A1 (en) 2020-08-04 2023-06-14 Venthera, Inc. Formulations of phosphoinositide 3-kinase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040009978A1 (en) * 2000-04-27 2004-01-15 Masahiko Hayakawa Fused heteroaryl derivatives
WO2006046040A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
WO2016187157A1 (en) * 2015-05-15 2016-11-24 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
網路文獻 STN CAS Registry Number: 1349711-67-6, Date Entered STN: 2011.12.06 *
網路文獻 STN CAS Registry Number: 1349711-67-6, Date Entered STN: 2011.12.06。

Also Published As

Publication number Publication date
SA521422728B1 (ar) 2023-12-26
MA54907A (fr) 2022-05-11
CN114072144A (zh) 2022-02-18
US12522614B2 (en) 2026-01-13
EP3920911A4 (en) 2023-03-08
AU2020219065A1 (en) 2021-09-23
MX2021009142A (es) 2021-10-13
JP2025036464A (ja) 2025-03-14
JP2022519317A (ja) 2022-03-22
KR20210124310A (ko) 2021-10-14
US20230416269A1 (en) 2023-12-28
JP7781250B2 (ja) 2025-12-05
EP3920911A1 (en) 2021-12-15
TW202045513A (zh) 2020-12-16
CA3127686A1 (en) 2020-08-13
SA522441650B1 (ar) 2024-02-29
IL285020B2 (en) 2025-11-01
US11661429B2 (en) 2023-05-30
WO2020163525A1 (en) 2020-08-13
US20200247816A1 (en) 2020-08-06
IL285020B1 (en) 2025-07-01
BR112021015353A2 (pt) 2021-10-05
SG11202108274SA (en) 2021-08-30
IL285020A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
JP7781250B2 (ja) 局所ホスホイノシチド3-キナーゼ阻害剤
ES2702541T3 (es) Pamoato de donepezilo, método de preparación y su uso
US20230331691A1 (en) Treprostinil derivative compounds and methods of using same
US8722672B2 (en) Topical pharmaceutical composition including rel-N-[6-[(2R,6S)-2,6-dimethyl-4-morpholinyl]-3-pyridinyl]-2-methyl-4′-(trifluoromethoxY)-[1,1′-biphenyl]-3-carboxamide
CN113336768B (zh) 一种多靶点酪氨酸激酶抑制剂
CN109475555A (zh) Pde-4抑制剂的局部配制品以及它们的使用方法
ES2523037T3 (es) Ésteres de metronidazol para el tratamiento de la rosácea
US20230190755A1 (en) Topical formulations of PI3K-delta inhibitors
CN103347498A (zh) 组蛋白脱乙酰酶抑制剂药物配方
JP2025514548A (ja) カレバスチンの塩及びその用途
CA2580910C (en) Pharmaceutical composition comprising temozolomide ester
TWI886312B (zh) 磷脂肌醇3-激酶抑制劑的調配物
CN111655675A (zh) 氨基烷基化合物
JP6131523B2 (ja) ロキソプロフェン含有外用剤
JP6625208B2 (ja) 経皮製剤